SANOFI (1SAN.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1SAN - FR0000120578 - Common Stock
1SAN.MI Key Statistics, Chart & Performance
The current stock price of 1SAN.MI is 78.89 EUR. In the past month the price decreased by -12.48%. In the past year, price decreased by -13.3%.
1SAN.MI Technical Analysis
1SAN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 1SAN.MI. 1SAN.MI has a medium profitability rating, but doesn't score so well on its financial health evaluation.
1SAN.MI Financial Highlights
Over the last trailing twelve months 1SAN.MI reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
1SAN.MI Forecast & Estimates
29 analysts have analysed 1SAN.MI and the average price target is 101.29 EUR. This implies a price increase of 28.4% is expected in the next year compared to the current price of 78.89.
For the next year, analysts expect an EPS growth of 2.37% and a revenue growth -0.09% for 1SAN.MI
1SAN.MI Ownership
1SAN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.31 | 190.34B | ||
| SNW.DE | SANOFI | 10.27 | 188.44B | ||
| 1MRK.MI | MERCK KGAA | 15.21 | 56.39B | ||
| MRK.DE | MERCK KGAA | 14.62 | 54.24B | ||
| UCB.BR | UCB SA | 39.6 | 49.45B | ||
| UNC.DE | UCB SA | 39.83 | 49.74B | ||
| 1BAYN.MI | BAYER AG-REG | 8.09 | 42.43B | ||
| BAYN.DE | BAYER AG-REG | 8 | 41.95B | ||
| IPN.PA | IPSEN | 13.01 | 11.20B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 23.57 | 9.71B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 105.53 | 9.77B | ||
| VIRP.PA | VIRBAC SA | 20.67 | 3.01B |
Related stock screener links
About 1SAN.MI
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 84587
Phone: 33153774000
SANOFI / 1SAN.MI FAQ
Can you describe the business of SANOFI?
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
What is the stock price of SANOFI today?
The current stock price of 1SAN.MI is 78.89 EUR. The price decreased by -4.31% in the last trading session.
What is the dividend status of SANOFI?
1SAN.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1SAN stock?
1SAN.MI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for 1SAN stock?
The PE ratio for SANOFI (1SAN.MI) is 10.38. This is based on the reported non-GAAP earnings per share of 7.6 and the current share price of 78.89 EUR.
What is the next earnings date for 1SAN stock?
SANOFI (1SAN.MI) will report earnings on 2026-01-29, after the market close.